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ABSTRACT
Objective: Age-related macular degeneration (ARMD) is the macular abnormality causing central vision loss in the elderly. One prevention for ARMD 
is the provision of antioxidants, such as lutein. Reduced form of glutathione (GSH) is a source of cysteine and sulfhydryl, playing a role in detoxification, 
transport, and metabolic processes. Both are prospected to have a synergistic effect in the prevention of ARMD. This study aimed to determine the 
efficacy of GSH addition in lutein supplementation to improve the contrast sensitivity of dry type ARMD patients.
Methods: This randomized controlled trial was conducted at an eye hospital and a tertiary general hospital from April 2016 to June 2016. This study 
involved 22 dry ARMD patients. Subjects were randomized and divided into treatment groups with 20 mg lutein with the addition of 500 mg GSH 
and 20 mg lutein only, for 30 days. Contrast sensitivity measurement was performed with Lea Numbers® Low Contrast Flip Chart before and after the 
treatment. Contrast sensitivity was analyzed comparatively with paired t-test.
Results: Contrast sensitivity improvement was observed in both the groups. Contrast sensitivity improvement of the group with additional GSH 
(3.62±1.44, p<0.05) was a 3-fold of the lutein group only (1.25±0.44, p>0.05). The result was statistically significant for the group treated with GSH 
addition.
Conclusion: GSH addition in lutein supplementation provoked better contrast sensitivity improvement in dry ARMD patients.
Keywords: Age-related macular degeneration, Glutathione, Lutein, Antioxidants, Contrast sensitivity.
INTRODUCTION
Age-related macular degeneration (ARMD) is a macular disorder 
characterized by one or more of several symptoms, namely drusen 
formation, retinal pigment epithelial (RPE) abnormalities in the form 
of hypopigmentation or hyperpigmentation, atrophic geography of 
retinal and choriocapillaris pigment epithelium involving the central 
part of the fovea, and neovascular maculopathy (exudative). Patients 
are usually older than 50 years old, who manifest with or without vision 
complaints in the form of central vision loss in one or both eyes [1-5].
ARMD is presently a major cause of blindness in western countries. 
Worldwide, ARMD sufferers reached 20–25 million people and 
expected to triple with the increase of elderly population in the next 
30–40 years. The World Health Organization estimated that currently 
8 million people experiencing blindness were caused by ARMD [4,5].
One prevention for ARMD is the provision of antioxidants. Glutathione 
(GSH) is one of the antioxidants in the body able to transform into 
reduced GSH. A compound containing sulfhydryl (-SH) group is basically 
divided into two groups, namely group of protein-SH and non-protein-
SH. GSH or y-glutamyl cysteinylglycine is a tripeptide containing 
cysteine and a source of sulfhydryl, which plays a role in detoxification, 
transport, metabolic processes, also as a cell antioxidant that works 
synergistically with fat antioxidants and solves fat peroxidation [6,7]. 
Previous studies mentioned that GSH was not properly absorbed if 
administered orally, but some others confirmed that GSH absorption in 
the intestinal epithelium underwent a specific uptake system. Disorders 
in GSH circulation process did not rule out the possibility of GSH oral 
administration [6-10]. Carotenoids, in this case, lutein and zeaxanthin, 
also possess antioxidant ability by improving macular pigment, which 
is believed to inhibit retinal damage due to oxidation by inhibiting the 
entry of blue light, thus reducing the risk of ARMD [11].
This study aimed to determine the efficacy of GSH addition in lutein 
supplementation to improve the contrast sensitivity of dry type ARMD 
patients.
METHODS
This study was a prospective, randomized, controlled trial with parallel 
group and 1:1 allocation ratio conducted at the Eye Hospital and Moh. 
Hoesin General Hospital, Palembang, Indonesia, from April 2016 to 
June 2016. Consents from participants were obtained and legitimated 
by signing an informed consent. This study obtained ethical approval 
from the Health Research Ethics Committee adhered to the tenets of 
the Declaration of Helsinki. No important changes were performed in 
methods after trial commencement.
Subjects’ eligibility
The study involved 22 dry type ARMD patients with the inclusion 
criteria of patients with age-related eye disease study (AREDS) 
category 2, 3, or 4, bilateral, visual acuity with the best correction 
>1.0 logMAR (5/50; 0.1), cooperative, and willing to follow the study 
until completion. Exclusion criteria were patients with blood glucose 
levels >150 mg/dl, signs of infection both in the anterior and posterior 
segments, optic disc abnormalities, visual axis opacities complicating 
the assessment of the posterior segment, and consumption of other 
antioxidants.
Subjects’ examination and treatment
Anamnesis was performed followed by ophthalmology examination 
to assess the anterior segment utilizing slit lamp (Carl Zeiss, 
Germany). Ophthalmoscopy examination with a 78 lens or indirect 
ophthalmoscopy (Neitz Instruments Co., Ltd., Japan) and fundus 
imaging with VisucamNM/FA (Carl Zeiss, Germany) were performed to 
establish the ARMD diagnosis. Participants with AREDS category 2, 3, 
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and 4 were selected. Patients were randomized by simple randomization 
using computer-generated tables of random numbers starting from 
the first row of the first column read from the right. The tables were 
numbered from 1 to 9. Patients with the number of 0-4 were placed in 
Group A, while patients with the number of 5-9 were placed in Group B. 
Patients included in Group A were given the treatment of 20 mg lutein 
(General Nutrition Centers, Inc., Pennsylvania, USA) and 500 mg GSH 
(General Nutrition Centers, Inc., Pennsylvania, USA), while Group B 
with 20 mg lutein only. The interventions were sealed in sequential 
numbered identical containers according to the allocation sequence 
by an assistant with no clinical involvement in the trial. Treatment was 
administered orally in capsule preparation and carried out for 30 days.
Contrast sensitivity measurement
Contrast sensitivity measurement was performed with Lea Numbers® 
Low Contrast Flip Chart before and after the treatment by a blinded 
investigator. The utilized lighting was within the illumination range 
of 60–120 cd/m2. The lowest visual threshold was determined using 
100% contrast from a distance of 3 m. The threshold used was 3 
symbols read correctly from a total of 5. The reading was repeated until 
the contrast of 2.5%. If at 2.5% contrast, symbol reading error at line 
1.0 was <3, subject was defined as having high contrast sensitivity. If at 
2.5% contrast, symbol reading error at line 1.0 was >3, or the reading 
failed to reach line 1.0, subject was defined as having low contrast 
sensitivity. Improved contrast sensitivity was defined with a decrease 
in the contrast value percentage correlated to the distance or increasing 
distance to the contrast value. There were no changes to trial outcomes 
after the trial commencement.
Data analysis
Data were analyzed with paired t-test for the contrast sensitivity 
measurement and Levene and Fisher tests for the baseline 
characteristics, processed with SPSS 21.0 (SPSS Inc., Chicago, USA) and 
presented in narrative and tabulation.
RESULTS
Recruitment and follow-up were enrolled from April 2016 to June 2016, 
with 10 study subjects who were obtained for each group, with a total 
of 20 subjects for both the groups. Treatment group of 20 mg lutein 
supplementation plus 500 mg GSH possessed slight older mean of age 
compared to 20 mg lutein group, as shown in Table 1. However, the difference 
in the mean of age between the two groups did not differ significantly. In the 
treatment group of 20 mg lutein supplementation plus 500 mg GSH, there 
were more men compared to women, whereas in the group of 20 mg lutein, 
men and women were equal in number. The difference in gender variable of 
the two groups was not statistically significant.
Contrast sensitivity before treatment was relatively equal between 
treatment group of 20 mg lutein plus 500 mg GSH and 20 mg lutein 
only, as shown in Table 2. After the treatment, contrast sensitivity 
improvement was observed in both the groups. Contrast sensitivity 
improvement of the group with additional GSH was 3-fold of the lutein 
group only, and the before-after difference was statistically significant, 
whereas in the treatment group of 20 mg lutein, no significant difference 
of contrast sensitivity was observed after treatment.
DISCUSSION
In this study, treatment group with additional GSH and lutein only 
possessed no statistically different mean of age. The mean of age in 
lutein and GSH group was 58.33±5.38 years and the lutein group was 
56.50±5.21 years. This was in accordance with previous study which 
stated that ARMD sufferers were mostly older than 50 years old, with 
or without vision complaints [1-5]. This may be due to the contrast 
sensitivity that decreases according to age and becomes sensitive to the 
effects of normal aging or a disease. The sensitivity of mesopic contrast 
decreases at the age of 50 years and over, followed by a decrease in 
photopic contrast sensitivity 10 years later. This corresponds to age-
related decrease in the number of rods in parafovea, which is more 
severe in cases of ARMD [12].
The result in this study which exhibited no significant difference in 
gender variable of ARMD patients was supported by Tang and Zhou 
study that conducted a contrast sensitivity examination with two stimuli. 
It was stated that there was no significant difference observed between 
men and women [13]. Similar results were also found in a study by 
Solberg and Brown who discovered that men and women exhibited no 
difference in contrast sensitivity and reaction time at spatial frequency 
tests [14]. One study that showed the difference in gender variable in 
ARMD patients was conducted by Richer et al., where older women 
experienced higher incidence of ARMD [15]. This difference was due to 
the small number of samples compared to previous studies.
Treatment group with only 20 mg lutein yielded no significant contrast 
sensitivity improvement in this study. This was in contrast to previous 
studies, including those conducted by Landrum et al., Olmedila et al., 
and Dagnelie et al. who evaluated visual function including contrast 
sensitivity, after lutein administration with doses varying between 10 
and 40 mg, with observed improvements [16-18]. In 1997, Landrum 
et al. stated that macular pigment density increased evenly within 
20–40 days with 30 mg lutein supplementation per day [16]. Gale 
et al. stated that the high amount of macular pigment would maintain 
visual sensitivity [19]. Olmedilla et al. discovered that improvement 
of visual function (visual acuity and glare sensitivity) occurred within 
3 months after 12–15 mg of lutein supplementation given 3 times a 
week in patients with ARMD [17], while Dagnelie et al. suggested that 
improvements in visual acuity and visual field began 2–4 weeks after 
the initiation of 40 mg lutein supplementation in patients with retinitis 
pigmentosa and other retinal degeneration [18]. Landrum et al. who 
observed that macular pigment density within 20–40 days from the 
initiation of 30 mg lutein supplementation in normal subjects showed 
an even increase, which was preceded by an increase in serum lutein 
concentration 10 day after the initiation of lutein supplementation [16]. 
Antioxidant properties of lutein were observed in a study by 
Purushothaman et al. as carbofuran-induced oxidative stress in rats was 
attenuated by lutein administration. Lutein reduced the neurotoxicity 
and tissue toxicity as observed from the elevated serum and tissue 
levels of acetylcholinesterase and decreased levels of creatine kinase, 
lactate dehydrogenase, and γ-glutamyltransferase [20].
Although contrast sensitivity improvement was observed in the 20 mg 
lutein group, it was not statistically significant. Possible causes to be 
considered were imperfect absorption of lutein due to inadequate 
carrier material, decreased intestinal villous absorptive function, 
and degenerative damage in RPE, resulting in insufficient macular 
pigment density to improve contrast sensitivity within 30 days after 
lutein administration. To prove this, further study is suggested with a 
Table 1: Baseline characteristics






Mean±SD 58.33±5.38 56.50±5.21 0.571a
Gender
Male n (%) 6/10 (60) 5/10 (50) 0.515b
Female n (%) 4/10 (40) 5/10 (50)
SD: Standard deviation, n: Number, aLevene test, bFisher’s test
Table 2: Contrast sensitivity improvement on lutein and 
glutathione treatment
Group Contrast sensitivity (mean±SD) p value
Before After Improvement
Lutein±glutathione 10.63±5.65 7.01±4.21 3.62±1.44 0.008a*
Lutein 10.25±6.17 9.00±6.61 1.25±0.44 0.177a
aPaired t-test, *p<0.05
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longer observational period or the determination of sample size, where 
previous studies conducted the span of observation for 12 months. 
Lutein molecule possesses poor water solubility and solution stability, 
susceptible to be degraded by oxygen and physical properties as light 
and heat. Innovative system of delivery is needed for lutein to be 
applied in clinical settings to preserve stability and elevate the level of 
uptake [21].
This study implicated that GSH was a favorable treatment option in 
ARMD. GSH addition in lutein supplementation provoked a significant 
better contrast sensitivity improvement compared to lutein only in 
dry ARMD patients. To be underlined, GSH is not well absorbed in 
the digestive tract, but a combination with several other antioxidants 
and standards or with N-acetylcysteine, alpha-lipoic acid, flavonoid 
silymarin, and L-glutamine has been proven to support and increase 
GSH levels in serum and tissues. This is also supported by Richer et al. 
which showed that the use of lutein in combination with carotenoids 
and other antioxidants or minerals significantly improved macular 
pigment density, visual acuity, and almost all visual quality examinations 
including contrast sensitivity [15]. When RPE cells cultured from 
humans were treated with 200 μm dimethyl fumarate (DMF) for 24 h, 
GSH concentration increased by 2.5 times. Increased level of GSH might 
be accompanied by a moderate increase in activity of GSH S-transferase, 
both of which lead to increased protection against peroxide poisoning. 
Without DMF treatment, almost all cells were lead to death with the 
treatment of 300–500 μm tertbutyl hydroperoxide (t-BHP) for 24 h. 
Pre-incubation of cells with DMF for 24 h provided protection against 
t-BHP induced by GSH oxidation, and the cells became more resistant to 
oxidative damage of t-BHP [22,23].
The improvement of contrast sensitivity in this study was due to 
the mutually reinforcing effects of lutein and GSH. GSH combination 
with other antioxidants increased the amount of GSH in the serum 
and tissues, thereby increasing the number of macular pigments 
density, RPE cells, and other cells in the body. This was consistent 
with a study conducted by Sabour-Pickett et al. which discovered 
that there was an increase in macular pigment density after lutein 
supplementation of 10 mg or a combination with other antioxidants 
or vitamins for 12 months [24]. GSH itself is a normal antioxidant 
present in the body, but exogenous addition will elevate its level in 
the body and tissues.
This study had limitations of small sample size and relatively short 
observation period. A larger sample size and a longer follow-up were 
required for better observation results. It is necessary to perform 
examination using a standard tool for contrast sensitivity assessments 
such as the Pelli Robson chart in future studies.
CONCLUSION
GSH addition in lutein supplementation was favorable as treatment 
option in ARMD as they exhibited better contrast sensitivity 
improvement in dry ARMD patients.
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